Get the Stockscreener App
104.87
0.61%
0.64
After Hours:
104.87
Celcuity Inc stock is traded at $104.87, with a volume of 413.39K.
It is up +0.61% in the last 24 hours and up +0.34% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$104.23
Open:
$104.73
24h Volume:
413.39K
Relative Volume:
0.50
Market Cap:
$4.85B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-39.13
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+0.57%
1M Performance:
+0.34%
6M Performance:
+109.49%
1Y Performance:
+745.04%
1-Day Range:
$102.01
$107.21
1-Week Range:
$97.49
$110.40
52-Week Range:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
104.87 | 4.82B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Adds Veteran Director to Strengthen Oncology Strategy - TipRanks
Celcuity Appoints Charles Romp to its Board of Directors - Yahoo Finance Singapore
Discipline and Rules-Based Execution in CELC Response - Stock Traders Daily
Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference - MarketBeat
CELC: Gedatolisib nears approval with strong efficacy, broad utility, and major commercial potential - TradingView
Candriam S.C.A. Increases Holdings in Celcuity, Inc. $CELC - MarketBeat
Inflation Data: Does Celcuity Inc align with a passive investing strategyJuly 2025 Pullbacks & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-02-08 07:23:47 - baoquankhu1.vn
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump - The Globe and Mail
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump - The Motley Fool
Wall Street Recap: Is Celcuity Inc stock a smart retirement pickGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Profit Review: Can Celcuity Inc ride the EV wave2025 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate - Yahoo Finance
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst By Investing.com - Investing.com South Africa
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst - Investing.com Canada
Biotech Stocks To ResearchFebruary 4th - MarketBeat
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Wealth Enhancement Advisory Services LLC Sells 10,476 Shares of Celcuity, Inc. $CELC - MarketBeat
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Insider Monkey
Jobs Data: Whats the beta of Celcuity Inc stockTrade Entry Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Behavioral Patterns of CELC and Institutional Flows - Stock Traders Daily
Atle Fund Management AB Takes $1.84 Million Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity granted FDA priority review for breast cancer therapy - MSN
Celcuity prices $248.7M debt, stock offerings - MSN
Celcuity Inc. (CELC) Stock Analysis: Navigating High Potential in Biotechnology with a $5.19 Billion Market Cap - DirectorsTalk Interviews
Assessing Celcuity (CELC) Valuation After FDA Priority Review Milestone For Gedatolisib - Sahm
Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock - MarketBeat
Celcuity stock hits all-time high at 116.65 USD By Investing.com - Investing.com Australia
Celcuity (CELC) Is Up 11.3% After FDA Grants Priority Review To Gedatolisib NDAWhat's Changed - simplywall.st
Celcuity (NASDAQ:CELC) Reaches New 52-Week HighTime to Buy? - MarketBeat
Celcuity stock hits all-time high at 116.65 USD - Investing.com
Celcuity Inc. Earnings Call: Strong Progress Amid Challenges - MSN
Celcuity, Inc. (NASDAQ:CELC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celcuity Inc: A Die To Be Cast Before July 2026 (NASDAQ: CELC) - Seeking Alpha
Celcuity Inc. (CELC) Stock Analysis: Exploring the Biotechnology Innovator’s Growth Potential - DirectorsTalk Interviews
Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain - Yahoo Finance
(CELC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
FDA accepts Celcuity’s NDA for gedatolisib with priority review By Investing.com - Investing.com South Africa
Celcuity wins FDA review for breast cancer drug (CELC:NASDAQ) - Seeking Alpha
FDA Accepts Celcuity's NDA For Gedatolisib In HR+, HER2- Advanced Breast Cancer - Nasdaq
FDA accepts Celcuity’s NDA for gedatolisib with priority review - Investing.com
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - manilatimes.net
Short Interest in Celcuity, Inc. (NASDAQ:CELC) Expands By 20.9% - MarketBeat
Is Celcuity Inc. stock gaining market shareEarnings Growth Summary & Daily Profit Maximizing Trade Tips - bollywoodhelpline.com
Dow Update: Can POAI lead its sector in growth2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Merger Talk: Is Madison Square Garden Sports Corp stock forming a cup and handleJuly 2025 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Chart Watch: Can Celcuity Inc disrupt its industryJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Nisa Investment Advisors LLC Buys 14,930 Shares of Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ:CELC) Shares Down 6.2%Should You Sell? - MarketBeat
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why - MSN
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):